Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print          Annual reports

Thursday 15 April, 2021

Alliance Pharma PLC

Directorate Change

RNS Number : 6343V
Alliance Pharma PLC
15 April 2021


   15 April 2021




("Alliance" or the "Group")


Directorate Change


Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Nigel Clifford, a Non-Executive Director, will leave the Group on 30 April 2021 after serving for six years. 


Nigel was appointed to Alliance's Board as a Non-Executive Director on 26 January 2015, since which time he has made a significant contribution to both the development and governance of the Group. Nigel's formal notice period has been waived by the Board owing to his other business commitments.


The recruitment process to appoint a replacement Non-Executive Director is underway and a further announcement will be made in due course.


David Cook, Alliance Pharma's Chairman, said: "On behalf of the Board, I extend our sincere thanks to Nigel for his wise counsel to the Board and its Committees as a Non-Executive Director during the past six years. During that time, Nigel has added significant value to Alliance, particularly in connection with the Group's international expansion, and we wish him well in his future endeavours."




For further information:


Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer


+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele

Corporate Broking: James Black


Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

Corporate Broking: Patrick Robb


About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website :


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t